Israel has established itself as a significant hub for biotechnology and pharmaceutical innovation, with numerous companies developing treatments for neurodegenerative diseases including Parkinson's disease[1]. The country's ecosystem combines world-class academic institutions, experienced biotech entrepreneurs, and strong venture capital support to create a fertile environment for neuroscience drug development.
Israeli biotech companies have made significant contributions to neuroscience research and drug development, leveraging strong academic institutions, experienced researchers, and a supportive ecosystem for innovation. The country's strategic location bridging US and European markets, combined with government incentives and funding programs, has created a robust foundation for biotechnology companies targeting neurological disorders. Israel's pharmaceutical sector has evolved from primarily generic manufacturing to innovative research and development, particularly in the neurosciences domain.
Pharma Two B is an Israeli biotech company focused on developing fixed-dose combination therapies for Parkinson's disease. The company's lead program, P2B001, combines pramipexole (a dopamine agonist) with entacapone (a COMT inhibitor) in a single tablet formulation[2].
The fixed-dose combination approach addresses a key clinical need in Parkinson's disease management. By combining two complementary mechanisms in a single pill, P2B001 simplifies the treatment regimen, improves patient compliance, and potentially reduces "off" time periods when medication wears off. The phase 3 trial enrolled over 500 patients with early-to-mid-stage Parkinson's disease, showing statistically significant improvements in motor function and quality of metrics compared to placebo[4].
BrainStorm Cell Therapeutics is developing NurOwn, an autologous cell therapy for neurodegenerative diseases that uses mesenchymal stem cells (MSCs) engineered to secrete elevated levels of neurotrophic factors including GDNF, BDNF, and HGF[5].
BrainStorm's NurOwn technology represents a novel cell therapy approach that addresses multiple pathological mechanisms in Parkinson's disease. The secreted GDNF (Glial Cell Line-Derived Neurotrophic Factor) promotes dopaminergic neuron survival and may potentially regenerate damaged neurons[7]. The Phase 2 trial in Parkinson's disease showed encouraging results with improvements in motor function and biomarker responses, and the company has received FDA fast track designation for the PD program[8].
Mapi Pharma focuses on enhanced formulations for CNS disorders, with particular emphasis on improving drug delivery to the brain. Their lead program GA-GLP-1 is a novel GLP-1 receptor agonist designed with enhanced brain penetration properties[9].
Mapi's approach addresses the significant challenge of delivering therapeutic molecules across the blood-brain barrier. Their proprietary formulation technology enables higher concentrations of GLP-1 agonists in the central nervous system, potentially improving efficacy while reducing the high doses required by existing formulations. GLP-1 receptor agonists have shown promise in multiple preclinical and clinical studies for Parkinson's disease, making this an attractive target for development.
RedHill Biopharma is a specialty pharmaceutical company with programs in gastrointestinal, infectious diseases, and emerging CNS pipelines. The company has leveraged its oral delivery technology to explore CNS indications.
Can-Fite BioPharma develops A3 adenosine receptor-targeted therapies for inflammation and neurodegeneration. Their lead compound piclidenoson (CF101) has been evaluated in Phase 2 trials for Alzheimer's disease[10].
The A3 adenosine receptor represents a novel therapeutic target in neurodegeneration. Preclinical studies demonstrated that A3AR activation leads to reduced inflammatory responses in microglia and protection against excitotoxic damage. Can-Fite's approach leverages the company's expertise in A3AR biology accumulated from their oncology and inflammatory disease programs.
Teva Pharmaceutical Industries is one of the world's largest generic drug manufacturers and a major Israeli pharmaceutical company with significant CNS expertise from decades of producing neurological medications[12].
Teva's global footprint and manufacturing capabilities position it as a key player in making Parkinson's treatments accessible worldwide. The company has also invested in specialty CNS products, including long-acting formulations and combination therapies.
Israel's academic institutions provide the scientific foundation for the country's biotech innovation:
Israel's biotech sector benefits from multiple support mechanisms that enable company formation and growth:
The Israeli research ecosystem includes specialized facilities supporting neurodegenerative disease research:
| Company | Program | Mechanism | Indication | Stage |
|---|---|---|---|---|
| Pharma Two B | P2B001 | Pramipexole + Entacapone | PD | Phase 3 |
| BrainStorm | NurOwn | MSC-GDNF/BDNF/HGF | PD | Phase 2 |
| Mapi Pharma | GA-GLP-1 | GLP-1 RA (enhanced BBB) | PD | Preclinical |
| Can-Fite | CF101 | A3AR agonist | AD | Phase 2 |
| RedHill | Opaganib | SK2 inhibitor | Neuroprotection | Preclinical |
Israeli biotech companies are targeting multiple therapeutic mechanisms in neurodegeneration:
The Israeli biotech ecosystem continues to evolve, with emerging areas of focus:
The global Parkinson's disease therapeutic market represents a significant opportunity for Israeli biotech companies. With over 10 million people living with Parkinson's worldwide and an aging global population, the demand for novel therapies continues to grow. The current market is valued at approximately $5 billion globally, with projections indicating 8-10% annual growth through 2030.
The key market drivers include:
Israeli companies are well-positioned to address these market opportunities through their innovative approaches to neurotrophic factor delivery, cell therapy, and novel small molecule development.
The Alzheimer's disease market represents an even larger opportunity, with over 55 million people affected globally and market value exceeding $10 billion. Israeli biotech companies are pursuing multiple therapeutic approaches including A3 adenosine receptor modulation (Can-Fite), GLP-1 receptor agonism (Mapi Pharma), and various neuroprotective strategies.
Israeli biotech companies benefit from a favorable clinical trial environment:
Clinical trials for Parkinson's and Alzheimer's disease typically measure:
Israeli companies have demonstrated capability to execute rigorous clinical trials meeting international regulatory standards.
Israeli biotech companies compete in the global neurodegenerative disease market against:
Israeli companies differentiate through:
| Advantage | Description | Example Companies |
|---|---|---|
| Academic collaboration | Strong ties to research institutions | All companies |
| Entrepreneurship culture | Experienced founders, serial entrepreneurs | BrainStorm, Can-Fite |
| Government support | Innovation Authority grants, tax incentives | All companies |
| Global partnerships | Licensing and collaboration with major pharma | Pharma Two B, Teva |
Israeli neurodegeneration companies have attracted significant investment:
Key investors in Israeli neuro-biotech include:
Israeli companies have successfully navigated FDA regulatory processes:
European market access is facilitated through:
Israeli biotech companies maintain active collaborations with academic institutions:
Several companies have established international research partnerships:
The Israeli neuro-biotech sector is positioned to address several emerging opportunities:
Key challenges include:
For continued success, Israeli neuro-biotech companies should:
Fixed-dose combination therapies in Parkinson's disease management. Movement Disorders. 2023. ↩︎
COMT inhibitors in Parkinson's disease: pharmacology and clinical outcomes. Journal of Neurology. 2024. ↩︎
Pharma Two B P2B001 Phase 3 efficacy and safety in Parkinson's disease. 2024. ↩︎
Phase 1/2 study of GDNF-secreting MSCs in Parkinson's disease. Nature Parkinsonism. 2024. ↩︎
Mesenchymal stem cells for neurodegenerative diseases: mechanisms and clinical potential. Stem Cell Research & Therapy. 2024. ↩︎
BDNF and neurotrophic factor therapies in Parkinson's disease. Molecular Neurobiology. 2024. ↩︎
BrainStorm Cell Therapeutics announces results from NurOwn phase 2 study in Parkinson's disease. 2024. ↩︎
GLP-1 receptor agonists in Parkinson's disease: clinical evidence and mechanisms. NPJ Parkinson's Disease. 2024. ↩︎ ↩︎
A3 adenosine receptor agonist CF101 in Alzheimer's disease: phase 2 results. Journal of Alzheimer's Disease. 2023. ↩︎
A3 adenosine receptor: a novel therapeutic target in neurodegeneration. Pharmacology & Therapeutics. 2023. ↩︎
Tel Aviv University neuroscience and biotechnology research. 2024. ↩︎